Annual EBITDA
-$9.97 M
-$28.18 M-154.72%
31 December 2023
Summary:
Ocuphire Pharma annual earnings before interest, taxes, depreciation & amortization is currently -$9.97 million, with the most recent change of -$28.18 million (-154.72%) on 31 December 2023. During the last 3 years, it has risen by +$7.80 million (+43.89%). OCUP annual EBITDA is now -154.72% below its all-time high of $18.22 million, reached on 31 December 2022.OCUP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$7.53 M
+$802.00 K+9.63%
30 September 2024
Summary:
Ocuphire Pharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$7.53 million, with the most recent change of +$802.00 thousand (+9.63%) on 30 September 2024. Over the past year, it has dropped by -$13.10 million (-234.97%). OCUP quarterly EBITDA is now -121.97% below its all-time high of $34.26 million, reached on 31 December 2022.OCUP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$28.36 M
-$13.10 M-85.89%
30 September 2024
Summary:
Ocuphire Pharma TTM earnings before interest, taxes, depreciation & amortization is currently -$28.36 million, with the most recent change of -$13.10 million (-85.89%) on 30 September 2024. Over the past year, it has dropped by -$56.67 million (-200.14%). OCUP TTM EBITDA is now -200.14% below its all-time high of $28.32 million, reached on 30 September 2023.OCUP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OCUP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -154.7% | -235.0% | -200.1% |
| 3 y3 years | +43.9% | -78.0% | +55.4% |
| 5 y5 years | - | - | - |
OCUP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -154.7% | +82.4% | -122.0% | +9.6% | -200.1% | +55.4% |
| 5 y | 5 years | -154.7% | +82.4% | -122.0% | +80.7% | -200.1% | +55.4% |
| alltime | all time | -154.7% | +82.4% | -122.0% | +80.7% | -200.1% | +55.4% |
Ocuphire Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$7.53 M(-9.6%) | -$28.36 M(+85.9%) |
| June 2024 | - | -$8.33 M(+8.0%) | -$15.25 M(+23.9%) |
| Mar 2024 | - | -$7.71 M(+60.8%) | -$12.31 M(+14.7%) |
| Dec 2023 | -$9.97 M(-154.7%) | -$4.79 M(-186.0%) | -$10.74 M(-137.9%) |
| Sept 2023 | - | $5.58 M(-203.5%) | $28.32 M(+55.5%) |
| June 2023 | - | -$5.39 M(-12.1%) | $18.21 M(-2.5%) |
| Mar 2023 | - | -$6.13 M(-117.9%) | $18.68 M(+2.5%) |
| Dec 2022 | $18.22 M | $34.26 M(-856.2%) | $18.22 M(-181.5%) |
| Sept 2022 | - | -$4.53 M(-8.0%) | -$22.35 M(+1.4%) |
| June 2022 | - | -$4.92 M(-25.3%) | -$22.05 M(-9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$6.59 M(+4.4%) | -$24.26 M(-57.2%) |
| Dec 2021 | -$56.69 M(+219.1%) | -$6.31 M(+49.2%) | -$56.69 M(-10.9%) |
| Sept 2021 | - | -$4.23 M(-40.7%) | -$63.63 M(+5.2%) |
| June 2021 | - | -$7.13 M(-81.7%) | -$60.47 M(+11.5%) |
| Mar 2021 | - | -$39.01 M(+194.3%) | -$54.25 M(+205.4%) |
| Dec 2020 | -$17.77 M(+273.4%) | -$13.25 M(+1141.0%) | -$17.77 M(+293.8%) |
| Sept 2020 | - | -$1.07 M(+16.8%) | -$4.51 M(+31.0%) |
| June 2020 | - | -$914.00 K(-63.9%) | -$3.44 M(+36.1%) |
| Mar 2020 | - | -$2.53 M | -$2.53 M |
| Dec 2019 | -$4.76 M | - | - |
FAQ
- What is Ocuphire Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Ocuphire Pharma?
- What is Ocuphire Pharma annual EBITDA year-on-year change?
- What is Ocuphire Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Ocuphire Pharma?
- What is Ocuphire Pharma quarterly EBITDA year-on-year change?
- What is Ocuphire Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Ocuphire Pharma?
- What is Ocuphire Pharma TTM EBITDA year-on-year change?
What is Ocuphire Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of OCUP is -$9.97 M
What is the all time high annual EBITDA for Ocuphire Pharma?
Ocuphire Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is $18.22 M
What is Ocuphire Pharma annual EBITDA year-on-year change?
Over the past year, OCUP annual earnings before interest, taxes, depreciation & amortization has changed by -$28.18 M (-154.72%)
What is Ocuphire Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of OCUP is -$7.53 M
What is the all time high quarterly EBITDA for Ocuphire Pharma?
Ocuphire Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $34.26 M
What is Ocuphire Pharma quarterly EBITDA year-on-year change?
Over the past year, OCUP quarterly earnings before interest, taxes, depreciation & amortization has changed by -$13.10 M (-234.97%)
What is Ocuphire Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of OCUP is -$28.36 M
What is the all time high TTM EBITDA for Ocuphire Pharma?
Ocuphire Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $28.32 M
What is Ocuphire Pharma TTM EBITDA year-on-year change?
Over the past year, OCUP TTM earnings before interest, taxes, depreciation & amortization has changed by -$56.67 M (-200.14%)